Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome



Status:Active, not recruiting
Conditions:Prostate Cancer, Cancer, Healthy Studies
Therapuetic Areas:Oncology, Other
Healthy:No
Age Range:18 - Any
Updated:11/8/2018
Start Date:December 4, 2009
End Date:April 2019

Use our guide to learn which trials are right for you!

This randomized pilot phase I trial studies the best way, either expressed prostatic
secretion (EPS) or post massage urine (PMU) biomarkers, of predicting biopsy results in
patients undergoing prostate biopsy. Studying samples of urine in the laboratory may help
doctors detect prostate cancer. It is not yet known whether EPS or PMU biomarkers are more
effective in predicting prostate biopsy results

OBJECTIVES:

I. To determine which non-invasive test for prostate cancer, EPS or PMU, is a better
predictor of prostate cancer biopsy result. (Part I)

II. To determine whether standardized testing for transmembrane protease, serine 2
(TMPRSS2):ERG Types III and VI is superior to testing for TMPRSS2:ERG Type III in predicting
prostate biopsy outcome. (Part I)

III. To expand the sample size utilizing the best TMPRSS2:ERG test and the best specimen type
as determined in objective I and II in order to estimate with reasonable accuracy the
positive predictive value (PPV) and negative predictive value (NPV) for each test. (Part II)

IV. To expand the biomarker set, to include Prostate Cancer Antigen 3 (PCA3)-ribonucleic acid
(RNA), d-glyceraldehyde-3-phosphate dehydrogenase (GADPH)-RNA, prostate-specific antigen
(PSA)-RNA, and deoxyribonucleic acid (DNA) methylation levels at glutathione s-transferase pi
(GSTP1), adenomatous polyposis coli (APC), retinoic acid receptor beta (RARB), Mitochondrial
DNA (MT-DNA) Deletions and ras association (RalGDS/AF-6) domain family 1 (RASSF1), so as to
develop an extensive data set for use in multivariate analysis. (Part II)

V. Use multivariate analysis to determine which combination of molecular markers offers the
greatest improvements in our ability to predict biopsy outcome over current baseline
predictors (Serum PSA and digital rectal examination [DRE]). (Part II)

VI. Estimate PPV and NPVs from this analysis and compare them to the standard assay's
performance. (Part II)

OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive digital
rectal palpation and then void a spontaneous urine sample for PMU analysis. Patients then
undergo a prostate biopsy.

ARM II: Patients receive DRE with prostatic massage for 30-60 seconds and are then milked at
the urethra to provide a collection of EPS. Patients then undergo a prostate biopsy.

Inclusion Criteria:

- All men who will be undergoing transrectal ultrasound of the prostate (TRUSP) with
biopsy in the department of Urology or participating urology clinics for the
evaluation of prostate cancer

Exclusion Criteria:

- Men with a previous diagnosis of prostate cancer

- Men without a prior diagnosis of prostate cancer but who have previously undergone a
biopsy for a suspicious DRE or PSA

- Men with a prior diagnosis of cancer < 5 years ago, excluding basal cell carcinoma
and/or squamous cell carcinoma
We found this trial at
5
sites
Arcadia, California 91006
Principal Investigator: Douglas O. Chinn
Phone: 626-574-7111
?
mi
from
Arcadia, CA
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Steven Smith, PhD
Phone: 800-826-4673
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Glendora, California 91741
Principal Investigator: Edward Davis
Phone: 626-335-0228
?
mi
from
Glendora, CA
Click here to add this to my saved trials
Monterey Park, California 91754
Principal Investigator: Felix Chi-Ming Yip
Phone: 213-687-3388
?
mi
from
Monterey Park, CA
Click here to add this to my saved trials
South Pasadena, California 91030
Principal Investigator: Roger W. Satterthwaite
Phone: 626-396-2900
?
mi
from
South Pasadena, CA
Click here to add this to my saved trials